US Patent Issued to Nuclidium, University of Basel on Oct. 21 for "Fibroblast activation protein (FAP) inhibitors, FAP conjugates, and diagnostic and therapeutic uses thereof" (Swiss, German Inventors)

ALEXANDRIA, Va., Oct. 28 -- United States Patent no. 12,447,217, issued on Oct. 21, was assigned to Nuclidium AG (Basel, Switzerland) and University of Basel (Basel, Switzerland).

"Fibroblast activation protein (FAP) inhibitors, FAP conjugates, and diagnostic and therapeutic uses thereof" was invented by Leila Jaafar-Thiel (Erlangen, Germany), Melpomeni Fani (Basel, Switzerland), Jacopo Millul (Basel, Switzerland) and Francesco De Rose (Munich).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present disclosure relates to the field of fibroblast activation protein (FAP) inhibitors, conjugates comprising the novel FAP inhibitors, including radiotracers, for the imaging, diagnosis and treatment of conditions ...